Plasmid DNA as Biotherapeutics
Safer alternative than viruses for gene therapy
Ease of administering by direct injection
Advantages over conventional vaccines:
- Low immunogenicity, thus allowing a course of multiple treatments
- Improved stability of the vaccine
- Stimulation of both B & T cell responses
- Absence of any infectious agents
- pDNA vector cassette is highly suitable for rapid development of various vaccine targets, e.g. personalized vaccines
- Relative ease of large scale manufacture
Quality Control of Plasmid DNA
* In compliance with FDA’s Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications
Our advantage
Proven track record in plasmid manufacturing for 10 years
Proprietary technologies (patent-pending) & know-hows that reduce cost and shorten the whole production cycle
High pDNA yields (> 100 g per batch)
Our know-hows overcome the bottlenecks of common lab-scale techniques and meet all regulatory requirements
Stringent QA & QC measures guarantee quality of our plasmid DNA
Support from HKSAR government in process development
Continual improvement in manufacturing process through collaboration with the Hong Kong Institute of Biotechnology